Asia-Pacific dengue treatment market is expected to reach USD 1,069.30 million by 2031, from USD 418.71 million in 2023, growing with a CAGR of 12.4% in the forecast period of 2024 to 2031.
Market Segmentation: Asia-Pacific Dengue Treatment Market, By Strains (DENV-2, DENV-3, DENV-1, DENV-4, and Others), Type (Vaccines and Acetaminophen), Severity (Mild to Moderate Dengue and Severe Dengue), Route of Administration (Parenteral and Oral), Mode of Purchase (Prescription and Over-the-Counter (OTC)), Gender (Male and Female), Age (Adult, Pediatric, and Geriatric), End User (Hospital, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies), By Countries (Japan, China, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines, Australia, and Rest of Asia-Pacific) - Industry Trends and Forecast to 2031
Overview of Asia-Pacific Dengue Treatment Market Dynamics: Driver
• Rising dengue incidence rate result in the demand for effective treatment Restrain
• Delay in the approval process of vaccines
Opportunity
• Growing number of pipeline vaccines for dengue treatment
Market Players: The key market players operating in the Asia-Pacific dengue treatment market are listed below: • Sanofi • Takeda Pharmaceutical Company Limited • Viatris Inc. • Johnson & Johnson • GSK plc. • Perrigo Company PLC • Baxter • Fresenius Kabi USA • Pfizer • Sun Pharmaceutical Industries Ltd • Teva Pharmaceuticals USA, Inc. • Aurobindo Pharma
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.
1 Introduction
1.1 Objectives Of The Study
1.2 Market Definition
1.3 Overview Of The Asia-pacific Dengue Treatment Market
Figure 11 Growing Pharmaceutical Industry Is Driving The Growth Of The Asia-pacific Dengue Treatment Market From 2024 To 2031
Figure 12 On The Basis Of Strains, The Denv-2 Segment Is Expected To Account For The Largest Share Of The Asia-pacific Dengue Treatment Market In 2024 And 2031
Figure 13 Drivers, Restraints, Opportunities, And Challenges Of Asia-pacific Dengue Treatment Market
Figure 14 Financial Budget For Vector-borne -diseases Including Dengue In India
Figure 15 Asia-pacific Dengue Treatment Market: By Strains, 2023